Seragon Pharmaceuticals Announces Closing Of Its Acquisition By Genentech

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Aug. 27, 2014 (GLOBE NEWSWIRE) -- Seragon Pharmaceuticals Inc., a leader in developing drugs for hormone dependent cancers, today announced the closing of its acquisition by Genentech, a member of the Roche Group, (SIX:RO) (SIX:ROG) (OTCQX:RHHBY). Deal terms included $725 million in cash up front along with $1.0 billion in contingent development milestone payments for total transaction value up to $1.725 billion. The acquisition includes Seragon's entire selective estrogen receptor degrader (SERD) program, including its most advanced compound, ARN-810, a next generation SERD that is currently being evaluated in a Phase I trial in postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+) breast cancer.

CONTACT: Susanne Whittenberg Seragon Pharmaceuticals Inc. (858) 369-7646

Seragon Pharmaceuticals Logo

Help employers find you! Check out all the jobs and post your resume.

Back to news